Trinity Biotech
TRIB
20 hedge funds and large institutions have $4.49M invested in Trinity Biotech in 2023 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 20 → 20 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
0.01% less ownership
Funds ownership: 0.81% → 0.8% (-0.01%)
24% less capital invested
Capital invested by funds: $5.93M → $4.49M (-$1.43M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $13K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HAIM
Hunter Associates Investment Management
Pittsburgh,
Pennsylvania
|
+$6.88K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$115 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$36.3K |
| 2 |
Morgan Stanley
New York
|
-$19.4K |
| 3 |
Renaissance Technologies
New York
|
-$7.87K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$3.62K |
| 5 |
RWMG
Redwood Wealth Management Group
Medford,
New Jersey
|
-$246 |
TRIB Hedge Fund Activity: Q3 2023 in Review
20 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q3 2023, worth a combined $4.49M — down 24% from $5.93M a quarter earlier.
Fund positioning in TRIB was balanced in Q3 2023: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 4 trimmed.
The largest buyer was Hunter Associates Investment Management, adding an estimated $6.88K. The largest seller was Citadel Advisors, exiting entirely with an estimated $36.3K sold.
- 20 institutional investors held Trinity Biotech (TRIB) as of Q3 2023, unchanged from Q2 2023.
- Funds reported $4.49M of Trinity Biotech stock for Q3 2023, down 24% quarter-over-quarter.
- 1 fund opened new Trinity Biotech positions in Q3 2023 and 1 closed out, a net change of 0 holders.
- The largest Trinity Biotech buyer in Q3 2023 was Hunter Associates Investment Management, an estimated $6.88K added.
- The largest Trinity Biotech seller in Q3 2023 was Citadel Advisors, an estimated $36.3K sold.
Based on aggregated 13F filings for Q3 2023.